BioCentury | Oct 21, 2013
Clinical News

Luseogliflozin: Phase III data

...The open-label, Japanese Phase III Study-2 in 299 Type II diabetics showed that once-daily oral luseogliflozin...
...HbA1c at week 52 compared to baseline (0.5% reduction from baseline, p<0.05). On secondary endpoints, luseogliflozin...
...treat Type II diabetes. Taisho Pharmaceutical Holdings Co. Ltd. (Tokyo:4581), Tokyo, Japan Product: Luseogliflozin ( TS-071...
BioCentury | Oct 21, 2013
Clinical News

Luseogliflozin: Phase III data

...Japanese Phase III Study-1 in 158 Type II diabetics showed that once-daily 2.5 mg oral luseogliflozin...
...from baseline to week 24 vs. placebo (placebo-adjusted reduction of 0.75%, p<0.001). On secondary endpoints, luseogliflozin...
...treat Type II diabetes. Taisho Pharmaceutical Holdings Co. Ltd. (Tokyo:4581), Tokyo, Japan Product: Luseogliflozin ( TS-071...
BioCentury | May 13, 2013
Clinical News

Luseogliflozin regulatory update

...Ministry of Health, Labor and Welfare (MHLW) for luseogliflozin (TS-071) to treat Type II diabetes. Luseogliflozin...
...cotransporter 2 (SGLT2) inhibitor. Taisho Pharmaceutical Holdings Co. Ltd. (Tokyo:4581), Tokyo, Japan Product: Luseogliflozin ( TS-071...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...in the U.S. and EU from Boehringer Ingelheim GmbH and Eli Lilly and Co. , luseogliflozin...
Items per page:
1 - 4 of 4